List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 508 studies with search of: Open Studies | "Multiple Myeloma"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Phase 1/2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Intervention: Biological: SNS01-T
2 Recruiting Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
3 Recruiting Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Conditions: Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
4 Recruiting Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Smoldering Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Radiation: total marrow irradiation;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Biological: filgrastim;   Genetic: fluorescence in situ hybridization;   Genetic: cytogenetic analysis;   Drug: cyclophosphamide;   Procedure: autologous-autologous tandem hematopoietic stem cell transplantation;   Drug: lenalidomide
5 Recruiting Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Drug: bortezomib;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: fludarabine phosphate;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Genetic: polymerase chain reaction
6 Recruiting 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
7 Recruiting A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
8 Recruiting Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Conditions: Multiple Myeloma;   Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: AT7519M, Bortezomib
9 Recruiting Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
10 Recruiting Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: vorinostat
11 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: intensity-modulated radiation therapy;   Radiation: total marrow irradiation;   Radiation: tomotherapy;   Drug: tacrolimus;   Drug: sirolimus
12 Recruiting Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: amifostine trihydrate;   Procedure: peripheral blood stem cell transplantation;   Genetic: fluorescence in situ hybridization;   Procedure: bone marrow ablation with stem cell support
13 Not yet recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
14 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
15 Unknown † Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
Conditions: Multiple Myeloma and Plasma Cell Neoplasm;   Renal Failure
Interventions: Drug: chemotherapy;   Drug: dexamethasone;   Procedure: plasmapheresis
16 Recruiting High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
17 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Drug: Lenalidomide & Dexamethasone
18 Recruiting Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: vorinostat;   Procedure: quality-of-life assessment;   Procedure: Correlative studies
19 Unknown † Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: obatoclax mesylate
20 Unknown † Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: alvocidib

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services